These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 35251319)

  • 1. Overview of systemic therapy options in liposarcoma, with a focus on the activity of selinexor, a selective inhibitor of nuclear export in dedifferentiated liposarcoma.
    Thirasastr P; Somaiah N
    Ther Adv Med Oncol; 2022; 14():17588359221081073. PubMed ID: 35251319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of the 12q amplicons in lipomatous soft tissue tumors by multiplex ligation-dependent probe amplification-based copy number analysis.
    Creytens D; Van Gorp J; Speel EJ; Ferdinande L
    Anticancer Res; 2015 Apr; 35(4):1835-42. PubMed ID: 25862836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data.
    Binh MB; Sastre-Garau X; Guillou L; de Pinieux G; Terrier P; Lagacé R; Aurias A; Hostein I; Coindre JM
    Am J Surg Pathol; 2005 Oct; 29(10):1340-7. PubMed ID: 16160477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selinexor versus doxorubicin in dedifferentiated liposarcoma PDXs: evidence of greater activity and apoptotic response dependent on p53 nuclear accumulation and survivin down-regulation.
    Zuco V; Pasquali S; Tortoreto M; Brich S; Percio S; Dagrada GP; Colombo C; Sanfilippo R; Lauricella C; Gounder M; El Bezawy R; Barisella M; Dei Tos AP; Casali PG; Gronchi A; Stacchiotti S; Zaffaroni N
    J Exp Clin Cancer Res; 2021 Mar; 40(1):83. PubMed ID: 33648535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GLI1 Coamplification in Well-Differentiated/Dedifferentiated Liposarcomas: Clinicopathologic and Molecular Analysis of 92 Cases.
    Sharma AE; Dickson M; Singer S; Hameed MR; Agaram NP
    Mod Pathol; 2024 Jun; 37(6):100494. PubMed ID: 38621503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The utility of fluorescence in situ hybridization (FISH) in determining DNA damage-inducible transcript 3 (DDIT3) amplification in dedifferentiated liposarcomas - an important diagnostic pitfall.
    Kuczkiewicz-Siemion O; Wiśniewski P; Dansonka-Mieszkowska A; Grabowska-Kierył M; Olszewska K; Goryń T; Prochorec-Sobieszek M; Rutkowski P; Szumera-Ciećkiewicz A
    Pathol Res Pract; 2021 Sep; 225():153555. PubMed ID: 34325315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential diagnosis of atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma: utility of p16 in combination with MDM2 and CDK4 immunohistochemistry.
    Kammerer-Jacquet SF; Thierry S; Cabillic F; Lannes M; Burtin F; Henno S; Dugay F; Bouzillé G; Rioux-Leclercq N; Belaud-Rotureau MA; Stock N
    Hum Pathol; 2017 Jan; 59():34-40. PubMed ID: 27597521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dedifferentiated liposarcoma and pleomorphic liposarcoma: a comparative study of cytomorphology and MDM2/CDK4 expression on fine-needle aspiration.
    Mariño-Enríquez A; Hornick JL; Dal Cin P; Cibas ES; Qian X
    Cancer Cytopathol; 2014 Feb; 122(2):128-37. PubMed ID: 24227706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of the MDM2/HMGA2 ratio and histological tumor grade in dedifferentiated liposarcoma.
    Yamashita K; Kohashi K; Yamada Y; Akatsuka S; Ikuta K; Nishida Y; Toyokuni S; Oda Y
    Genes Chromosomes Cancer; 2021 Jan; 60(1):26-37. PubMed ID: 33111425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Well-differentiated liposarcomas and dedifferentiated liposarcomas: Systemic treatment options for two sibling neoplasms.
    Kyriazoglou A; Pagkali A; Kotsantis I; Economopoulou P; Kyrkasiadou M; Moutafi M; Gavrielatou N; Anastasiou M; Boulouta A; Pantazopoulos A; Giannakakou M; Digklia A; Psyrri A
    Cancer Treat Rev; 2024 Apr; 125():102716. PubMed ID: 38492514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon.
    Italiano A; Bianchini L; Keslair F; Bonnafous S; Cardot-Leccia N; Coindre JM; Dumollard JM; Hofman P; Leroux A; Mainguené C; Peyrottes I; Ranchere-Vince D; Terrier P; Tran A; Gual P; Pedeutour F
    Int J Cancer; 2008 May; 122(10):2233-41. PubMed ID: 18214854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and biological significance of CDK4 amplification in well-differentiated and dedifferentiated liposarcomas.
    Italiano A; Bianchini L; Gjernes E; Keslair F; Ranchere-Vince D; Dumollard JM; Haudebourg J; Leroux A; Mainguené C; Terrier P; Chibon F; Coindre JM; Pedeutour F
    Clin Cancer Res; 2009 Sep; 15(18):5696-703. PubMed ID: 19737942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dedifferentiated liposarcoma with "homologous" lipoblastic (pleomorphic liposarcoma-like) differentiation: clinicopathologic and molecular analysis of a series suggesting revised diagnostic criteria.
    Mariño-Enríquez A; Fletcher CD; Dal Cin P; Hornick JL
    Am J Surg Pathol; 2010 Aug; 34(8):1122-31. PubMed ID: 20588177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.
    Peng T; Zhang P; Liu J; Nguyen T; Bolshakov S; Belousov R; Young ED; Wang X; Brewer K; López-Terrada DH; Oliveira AM; Lazar AJ; Lev D
    Lab Invest; 2011 Mar; 91(3):392-403. PubMed ID: 21060307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dedifferentiated Liposarcoma: Systemic Therapy Options.
    Gahvari Z; Parkes A
    Curr Treat Options Oncol; 2020 Feb; 21(2):15. PubMed ID: 32026050
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can MDM2 and CDK4 make the diagnosis of well differentiated/dedifferentiated liposarcoma? An immunohistochemical study on 129 soft tissue tumours.
    Aleixo PB; Hartmann AA; Menezes IC; Meurer RT; Oliveira AM
    J Clin Pathol; 2009 Dec; 62(12):1127-35. PubMed ID: 19946100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of CDK4 as prognostic biomarker in Soft Tissue Sarcoma and synergistic effect of its inhibition in dedifferentiated liposarcoma sequential treatment.
    Vanni S; Miserocchi G; Gallo G; Fausti V; Gabellone S; Liverani C; Spadazzi C; Cocchi C; Calabrese C; De Luca G; Bassi M; Gessaroli M; Tomasetti N; Campobassi A; Pieri F; Ercolani G; Cavaliere D; Gurrieri L; Riva N; Recine F; Ibrahim T; Mercatali L; Jones R; De Vita A
    Exp Hematol Oncol; 2024 Aug; 13(1):74. PubMed ID: 39103896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on genomic and molecular landscapes of well-differentiated liposarcoma and dedifferentiated liposarcoma.
    Lu J; Wood D; Ingley E; Koks S; Wong D
    Mol Biol Rep; 2021 Apr; 48(4):3637-3647. PubMed ID: 33893924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Telomere as a Therapeutic Target in Dedifferentiated Liposarcoma.
    Alessandrini I; Percio S; Naghshineh E; Zuco V; Stacchiotti S; Gronchi A; Pasquali S; Zaffaroni N; Folini M
    Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole exome sequencing of well-differentiated liposarcoma and dedifferentiated liposarcoma in older woman: a case report.
    Zhao Z; Chen X; Xu J; Shi Y; Mak TK; Huo M; Zhang C
    Front Med (Lausanne); 2023; 10():1237246. PubMed ID: 37649981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.